PRESS RELEASE
News
-
-
-
PRESS RELEASE
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Sanofi and Regeneron's Dupixent approved as first biologic medicine for young children with uncontrolled chronic spontaneous urticaria, expanding previous approval for adults and adolescents -
-
-
PRESS RELEASE
Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
Sanofi's Nuvaxovid COVID-19 vaccine demonstrated better tolerability than mNEXSPIKE in a head-to-head study presented at ESCMID Global Congress. Results indicate lower side effects and improved patient experience -
-
-
PRESS RELEASE
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
Sanofi and Regeneron's Dupixent approved in the EU for young children with chronic spontaneous urticaria, expanding treatment options to address type 2 inflammation -
